Common Contracts
4 similar Exclusive Ip License Agreement contracts by Aratana Therapeutics, Inc.
EX-10.17 21 d503089dex1017.htm EX-10.17 Execution Version EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005Exclusive Ip License Agreement • May 5th, 2020 • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (this “Agreement”) is entered into as of December 27, 2010 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005Exclusive Ip License Agreement • June 6th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (this “Agreement”) is entered into as of December 27, 2010 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005Exclusive Ip License Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (this “Agreement”) is entered into as of December 27, 2010 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005Exclusive Ip License Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (this “Agreement”) is entered into as of December 27, 2010 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
